Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 5Phase 3 4Phase 1/2 4Phase 4 1

Status

Completed 10Unknown 5Terminated 4Active not recruiting 4Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 2Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × regorafenib × Clear all
NCT05770882 2025-03-11

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Great Novel Therapeutics Biotech & Medicals Corporation

Phase 1/2 Terminated
7 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03563157 2024-12-11

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

ImmunityBio, Inc.

Phase 1/2 Terminated
2 enrolled 13 charts
Gastrointestinal

Colorectal Neoplasms

NCT03555149 2023-11-07

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Hoffmann-La Roche

Phase 1/2 Terminated
96 enrolled 24 charts
Gastrointestinal

Colorectal Neoplasms

NCT03722108 2023-10-16

REGIRI

UNICANCER

Phase 1/2 Terminated
89 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡